BMJ Open Timeliness of diagnosis of breast and cervical cancers and associated factors in low-income and middle-income countries: a scoping review

Chukwudi A Nnaji ^{1,2}, Elochukwu F Ezenwankwo ^{1,2}, Paul Kuodi ³,
Fiona M Walter ^{4,5}, Jennifer Moodley ^{1,2}

To cite: Nnaji CA, Ezenwankwo EF, Kuodi P, *et al*. Timeliness of diagnosis of breast and cervical cancers and associated factors in low-income and middle-income countries: a scoping review. *BMJ Open* 2022;**12**:e057685. doi:10.1136/bmjopen-2021-057685

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2021-057685>).

Received 27 September 2021
Accepted 19 January 2022

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Dr Chukwudi A Nnaji;
nnjchu001@myuct.ac.za

ABSTRACT

Objectives Addressing the barriers to early breast and cervical cancer diagnosis in low and middle-income countries (LMICs) requires a sound understanding and accurate assessment of diagnostic timeliness. This review aimed to map the current evidence on the time to breast and cervical cancer diagnosis and associated factors in LMICs.

Design Scoping review.

Sources MEDLINE (via PubMed), Cochrane Library, Scopus and CINAHL.

Eligibility criteria Studies describing the time to diagnosis and associated factors in the context of breast and cervical cancer in LMICs published from 1 January 2010 to 20 May 2021.

Study selection and data synthesis Two reviewers independently screened all abstracts and full texts using predefined inclusion criteria. The review was reported in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews. Evidence was narratively synthesised using predefined themes. **Results** Twenty-six studies conducted across 24 LMICs were included in the review, most (24/26) of which focused on breast cancer. Studies varied considerably in their conceptualisation and assessment of diagnostic time, events, intervals and delays, with a minority of the studies reporting the use of validated methods and tools. Patient-related intervals and delays were more frequently evaluated and reported than provider-related and health system-related intervals and delays. Across studies, there were variations in the estimated lengths of the appraisal, help-seeking, patient and diagnostic intervals for both cancers and the factors associated with them.

Conclusions Despite the significant burden of breast and cervical cancer in LMICs, there is limited information on the timeliness of diagnosis of these cancers. Major limitations included variations in conceptualisation and assessment of diagnostic events and intervals. These underscore the need for the use of validated and standardised tools, to improve accuracy and translation of findings to better inform interventions for addressing diagnostic delays in LMICs.

INTRODUCTION

Breast and cervical cancer constitute a growing public health burden globally.^{1 2} The incidence, morbidity and mortality burdens of both cancers

Strengths and limitations of this study

- This scoping review was conducted in accordance with an enhanced evidence synthesis methodology and reported using standard reporting guidelines.
- This review updates the evidence base relating to the nature of the time to diagnosis of breast and cervical cancer and associated factors in low and middle-income countries.
- Literature searches were comprehensive, covering both peer-reviewed and relevant grey literature.
- Due to the broad nature of the topic, it is possible that not all relevant evidence sources were identified by the search strategy, however comprehensive.

are disproportionately high among women in low and middle-income countries (LMICs).^{2 3} Breast cancer is the most commonly occurring cancer and the leading cause of cancer deaths among women worldwide, with an age-standardised incidence rate (ASIR) of 31 per 1 00 000 women in LMICs.^{4 5} Cervical cancer is the fourth most common cancer among women, with an ASIR of 16 per 1 00 000 women.² Cancer survival rates are low in LMICs, the major attributable factors of which include late-stage diagnosis and suboptimal access to quality healthcare.^{1 6}

Timely diagnosis is critical for optimising patients' navigation of the pathway from cancer symptom awareness to treatment, and improving survival.^{7–9} However, the majority of breast and cervical cancers are diagnosed at a late stage when treatment is often less effective and more expensive.^{10–12} In LMICs, barriers to timely cancer diagnosis include individual and disease-related factors as well as health system constraints.^{13–15} Individual-level factors may include demographic, behavioural and psychosocial factors, in addition to those associated with underlying socio-cultural barriers to timely diagnosis, such as lay beliefs that cancers are contagious and

that they are inevitably fatal.^{16 17} Disease-related factors include those related to the site, size, clinical manifestation and growth of tumours.¹⁵ Health system factors in LMICs include health policy, access, quality and service delivery barriers, such as inadequate diagnostic capacity, weak referral systems, suboptimal access to treatment and insufficient human resources.^{6 18 19} While there is substantial evidence on the association between these factors and cancer diagnostic delays, not much is known about the extent to which they influence time to diagnosis and diagnostic intervals, particularly in LMICs.

Various approaches and tools have been used for assessing time to diagnosis and diagnostic intervals, while their use in LMICs has grown over the years.^{17 19 20} However, the tools commonly used often ignore existing models of patient behaviour and are poorly or inadequately validated.^{15 21 22} To bolster better conceptual understanding of patient's navigation, Walter, Scott and colleagues proposed a Model of Pathways to Treatment that describes the distinct phases of cancer patients' pathways from symptom awareness to diagnosis and treatment.^{15 22} To aid the development of valid tools for measuring time to cancer diagnosis, the Aarhus checklist has been proposed for guiding the design and reporting of early cancer diagnosis studies.²³

A good understanding of the timeliness of breast or cervical cancer diagnosis, the diagnostic intervals and associated factors is important to guide interventions for addressing the growing public health problem of diagnostic delays in LMICs.^{24–26} In 2017, the WHO published the *WHO Guide to Cancer Early Diagnosis* to provide a global standard for addressing barriers that may impede timely cancer diagnosis and treatment.^{27 28} Addressing these barriers requires an accurate assessment and understanding of the time to diagnosis, related intervals and the multidimensional factors associated with the timeliness of diagnosis.²⁸

This review aims to provide an updated and comprehensive synthesis of the evidence on the time to diagnosis and its associated factors, in the context of symptomatic breast and cervical cancer diagnosis in LMICs. It contributes a systematically organised evidence summary for health policymakers, cancer programme managers, oncologists and other cancer care providers for guiding policy and practice decision-making. In addition, the findings will be useful for informing the design of interventions and strategies for addressing existing breast and cervical cancer diagnostic delays in resource-limited settings, while identifying gaps for future research efforts at measuring and appraising diagnostic timeliness.

METHODS AND ANALYSIS

Conceptual framework

This scoping review used the Model of Pathways to Treatment to map the identified evidence on the timeliness, time intervals and associated factors of breast and cervical cancer diagnosis.^{15 22} The framework specifies

the essential events, processes and time intervals that may occur in the period prior to diagnosis and the start of medical treatment and identifies the factors that may influence each interval.

Study design

The design of this study was guided by Arksey and O'Malley's scoping review methodology,²⁹ as enhanced by Levac and colleagues.³⁰ The enhanced framework involves six stages for undertaking a scoping review: (1) identifying the research question, (2) identifying the relevant studies (defining the inclusion and exclusion criteria), (3) searching and selecting the evidence, (4) charting the evidence, (5) collating, summarising and reporting the evidence and (6) consultation with relevant stakeholders. The review was reported in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews.³¹ Full details of the study design have been published elsewhere.³²

Data sources

The literature search was guided by the review objectives and the population, concept and content (PCC) criteria. The search strategy was developed with guidance from a health sciences subject librarian and applied in accordance with the Peer Review of Electronic Search Strategies guidelines.³³ The search strategy was pretested prior to the actual search. Search terms and free-text words were combined using the Boolean operators 'AND' and 'OR'. Search terms included the use of controlled descriptors (such as MeSH terms, CINAHL and headings) and their synonyms. In order to restrict search to LMICs, a location filter containing all countries currently classified as part of LMICs and synonymous geographical, regional and economic categorisations were incorporated. The search strategy, as applied to the various literature databases, is outlined in the online supplemental appendix. More details of the search strategy are described in the review protocol published elsewhere.³²

A comprehensive literature search was conducted on the following electronic databases: MEDLINE (via PubMed), Cochrane Library (including the Cochrane Central Register of Controlled Trials (CENTRAL) and the Database of Abstracts of Reviews of Effects (DARE)), Scopus, CINAHL and the International Clinical Trials Registry Platform (ICTRP). Additionally, relevant grey literature sources were searched for potentially eligible articles, including the publication database of the WHO's International Agency for Research on Cancer (IARC), the Cancer Atlas of the Union for International Cancer Control (UICC) and the Global Cancer Project Map. A hand-search of reference lists of included studies was conducted. For recency, only articles published from 1 January 2010 to the last date of search (20 May 2021) were considered eligible. No language restrictions were applied. Non-English potentially eligible articles would have been translated using a Web-based translation tool.³⁴

Eligibility criteria

Inclusion criteria were defined using the PCC framework, proposed by Peters and colleagues.³⁵ Eligible population included women with breast or cervical cancer and healthcare providers (HCP) in LMIC contexts. The definition of LMICs was based on the World Bank's current classification using per capita gross national income.³⁶ The concepts of interest were time to diagnosis and diagnostic intervals of breast and/or cervical cancers. To be considered eligible for inclusion, studies need to have measured time to diagnosis in the context of breast and/or cervical cancer diagnosis in LMICs, using specific methods, tools or strategies; and/or assessed diagnostic intervals of breast and/or cervical cancers; whether or not they evaluated the factors associated with diagnostic time or time intervals. Multinational literature involving LMIC and non-LMIC countries and meeting inclusion criteria were eligible for inclusion, except where country-specific information could not be abstracted. Similarly, articles involving multiple cancer types were eligible for inclusion, except relevant cancer type-specific information could not be abstracted.

Articles focused solely or mainly on theoretical and conceptual understanding of timeliness of breast or cervical cancer diagnosis were excluded, as were those assessing cancer patient pathways that are not related to diagnostic time and intervals. Studies focused primarily on screening of asymptomatic individuals were also excluded. Study design eligibility included randomised trials, non-randomised trials and observational studies, with or without controls. Only primary studies were included, while systematic, scoping reviews and other forms of aggregated evidence were excluded.

Study selection

The review process consisted of two levels of screening. For the first level of screening, two reviewers (CAN and PK) independently screened the titles and abstracts of all retrieved records from the search output. Articles considered relevant by either or both of the reviewers were included in the full-text assessment. Following the removal of duplicates, full texts of remaining studies were retrieved. In the second step, the two reviewers (CAN and EFE) independently assessed the full-texts to determine whether they met the inclusion/exclusion criteria. Disagreements in eligibility assessment were resolved through consensus between.

Data extraction

Two reviewers (CAN and EFE) independently abstracted data from all included studies using a standardised data abstraction tool, adapted from the framework proposed by Carlos and colleagues.³⁷ The tool includes four domains: (1) study identification details (article title, journal title, authors, country of the study, language, publication year, host institution of the study), (2) methodological characteristics (study design, study objective or research question or hypothesis, sample characteristics

(eg, sample size, sex, age, ethnicity, groups and controls, follow-up duration, validation of measures, statistical analyses), (3) main findings and (4) conclusions. Study eligibility was reverified at the start of/during data extraction. Any discrepancies in the abstracted data between the two reviewers were resolved by discussion. CAN combined the two spreadsheets of abstracted data for analysis. JM and FMW reviewed analysed data for accuracy and consistency with protocol.

Data analysis

Findings were narratively summarised and reported based on themes that emerged from the charted evidence. Where applicable, quantitative evidence was aggregated using summary statistics. Time to diagnosis and diagnostic intervals were described based on the Model of Pathways to Treatment.^{15 22} The Model also allowed for the assessment of patient; HCP and health system and disease-related factors that could influence diagnostic timeliness.

Patient and public involvement

Patients or the public were not involved in this research.

RESULTS

Search results

A total of 10 591 records were identified from literature database searches. After the removal of duplicates, there were 9347 unique records. These were screened by their titles and abstracts, following which 9174 clearly ineligible publications were excluded. The full texts of the remaining 173 potentially eligible studies were reviewed against predefined inclusion and exclusion criteria; 26 of which were included in the review, while 147 were excluded for various reasons. Figure 1 presents

Figure 1 PRISMA flowchart of the study selection process. LMICs, low and middle-income countries; PRISMA, Preferred Reporting Items for Systematic reviews and Meta-Analyses.

Figure 2 Geographical distribution of included studies.

the PRISMA flowchart of the study selection process and reasons for exclusion.

Characteristics of included studies

Online supplemental table 1 describes the characteristics of included studies. Most (24/26) of the studies were focused on breast cancer, with only two focusing on cervical cancer. The studies were published between 2011 and 2020, conducted across 24 LMICs across the regions of Africa, Europe, Latin America, Middle-East Asia and South-East Asia. The following countries (number of studies) were represented: Bulgaria (1), Colombia (1), Ethiopia (3), Haiti (1), India (2), Iran (1), Libya (1), Malaysia (2), Mali (1), Mexico (1), Namibia (1), Nepal (1), Nigeria (3), Peru (1), Pakistan (3), Russia (1), Rwanda (1), Serbia (1), South Africa (2), Sudan (1), Thailand (1), Turkey (1), Uganda (1) and Zambia (1). **Figure 2** illustrates the geographical distribution of included studies.

Nearly, all (24/26) of the studies included were quantitative in design, including cross-sectional (21), cohort-type longitudinal (2) and case-control (1) studies. One study had a mixed-methods cross-sectional design, while another was a qualitative study. Most (24/26) of studies primarily focused on breast cancer, whereas the remaining two focused on cervical cancer. Participants were mostly adult women with newly diagnosed breast or cervical cancer. All of the studies were conducted within healthcare settings, of which 18 were urban, 3 were rural and 5 were both rural and urban.

Methods of diagnosis

In the majority (20/26) of the studies, diagnosis was defined based on pathological or histological confirmation.^{7 18 19 38–54} The rest of the studies relied on clinical assessment as a diagnostic modality.^{55–60}

Methods/tools used for assessing diagnostic timeliness and intervals

Online supplemental table 1 describes the various methods and tools used for assessing diagnostic timeliness and intervals across studies. In most (23/26) of

the studies, diagnostic events, timeliness and intervals were assessed using questionnaires or interviews that relied on participants' recall,^{7 18 19 38–56 59} seven of which combined patients' reports obtained from questionnaires or interviews with diagnostic information derived from facility-based medical records.^{40 43 50 52–54 59} Three studies assessed diagnostic events and intervals using medical records.^{38 57 60}

To define diagnostic time and intervals, 14 studies relied on authors' definition^{18 38–41 44 45 49 52–54 57 59} while four adopted definitions from previous studies.^{47 50 51 56} Four studies adopted the Model of Pathways to Treatment,^{7 19 43 55} three studies adopted the Aarhus Statement,^{42 46 55} while two studies adopted the Anderson Model.^{48 58}

The studies varied considerably in the use of common terminologies relating to diagnostic events and intervals. Only two studies defined the appraisal interval (time between discovery of symptoms and perceiving reasons to seek help) and help-seeking interval (time between symptom recognition and first HCP consultation) as separate intervals as defined by the Model of Pathways to Treatment.^{7 55} Most other studies combined both appraisal and help-seeking intervals as a single interval (time between symptom recognition and first HCP visit/consultation). Varying terminologies were used across studies to refer to this single interval, including help-seeking interval,^{43 55} patient (-related) interval (also patient delay or patient time),^{7 18 42 44–47 49–54 58 59} time to action,⁵⁶ precontact time,⁴¹ consultation time^{40 48} and presentation interval.⁶⁰ **Table 1** describes how diagnostic timeliness and intervals were defined across studies.

Diagnostic interval was defined in various ways across studies: the time commencing from the point of symptom detection to diagnosis,^{40 48 57} time from first clinical consultation to diagnosis^{7 18 19 41 42 44 47 49 50 52 54} and time from first presentation at a diagnostic centre to diagnosis.⁴⁶ Notably, the diagnostic interval was also referred to as primary care interval (time between first HCP visit and first specialist visit).^{44 46 55} Less than half (10/26) of the studies defined total diagnostic interval (time from symptom detection to diagnosis).^{19 38–41 44 47 48 50 55}

Table 1 Diagnostic timeliness and intervals as assessed by included studies

Study ID	Cancer site	Study design	Country	Diagnostic timeliness and intervals assessed
Agodirin <i>et al</i> ⁵⁵	Breast	Cross-sectional	Nigeria	Appraisal interval: time (days) from the detection of first breast symptom to first disclosure (eg, to partners, family and friends) Help-seeking interval: time (days) between symptom detection and first HCP visit Primary care interval: time (days) between first HCP visit and first specialist visit Specialist care interval: time (days) between symptom detection and first specialist visit
Begoihn <i>et al</i> ³⁸	Cervix	Retrospective cohort	Ethiopia	Patient interval: time (weeks) between patient reported onset of symptoms and pathological diagnosis
Dianatinasab <i>et al</i> ³⁹	Breast	Cross-sectional	Iran	Delay time: interval (days) between the date that patient noticed the first breast cancer symptom until the date that pathology report was issued
Dye <i>et al</i> ⁵⁶	Breast	Mixed methods observational	Ethiopia	Time to action: time (years) between symptom detection and first HCP visit
Ermiah <i>et al</i> ⁴⁰	Breast	Cross-sectional	Libya	Consultation time: time (months) from first symptom to first HCP visit. Diagnostic time: time (months) from the date of the first symptoms to the date of final breast cancer diagnosis
Foerster <i>et al</i> ⁴¹	Breast	Cohort study	Multi-country: Nigeria, Namibia, Uganda and Zambia	Pre-contact interval: time (months) between date of symptom discovery to first HCP visit Post-contact interval: time (months) between first HCP visit to definitive diagnosis Total diagnostic interval: pre-contact interval +post-contact interval
Gebremariam <i>et al</i> ⁴²	Breast	Cross-sectional	Ethiopia	Patient interval: time (days) from recognition of first symptom to date of first clinical consultation Diagnostic interval: time (days) from first clinical consultation to the date of diagnosis
Grosse Frie <i>et al</i> ⁴³	Breast	Cross-sectional	Mali	Help-seeking interval: time (days) from date of first symptom recognition to date of first HCP visit. Diagnostic interval: time (days) from first HCP visit to date of receiving pathology results
Gyenwali <i>et al</i> ⁴⁴	Cervix	Cross-sectional	Nepal	Patient delay: time (days) between symptom awareness and first HCP visit (≥ 60 days was defined as long) HCP delay: time (days) between first HCP visit and final referral by HCP to the cancer diagnostic centre (>7 days was defined as long) Referral delay: time (days) between the date of final referral to diagnostic centre and first appointment at the cervical cancer diagnostic centre (>7 day was referred as long). Diagnostic waiting time: time (days) for all relevant investigations of symptoms in the diagnostic centre (>7 days was defined long waiting time). Total diagnostic delay: patient delay +HCP delay +referral delay +diagnostic waiting time (>90 days was referred as long)

Continued

Table 1 Continued

Study ID	Cancer site	Study design	Country	Diagnostic timeliness and intervals assessed
Jassem <i>et al</i> ⁴⁵	Breast	Cross-sectional	Multi-country: Bulgaria, India, Russia, Serbia and Turkey	Patient-related delay time: time (weeks) between the onset of first symptoms and the first medical visit. System-related delay time: time (weeks) between the first medical visit and the start of therapy. Total delay time: sum of the patient-related delay and system-related delay time
Khaliq <i>et al</i> ⁴⁶	Breast	Cross-sectional	Pakistan	Patient interval: time (days) between experiencing signs and symptoms and seeking first care. Referral interval: time (days) between presentation and referral to a diagnostic centre; Diagnostic interval: time (days) from presentation at a diagnostic centre to receipt of a diagnosis of breast cancer
Khokher <i>et al</i> ⁵⁷	Breast	Cross-sectional	Pakistan	Diagnostic delay: time (years) between symptom detection and first HCP visit
Martínez-Pérez <i>et al</i> ⁴⁷	Breast	Cross-sectional study	Colombia	Patient interval: time (days) between detection of the first sign/symptom and the first medical consultation. Provider interval: time (days) between the first medical consultation and diagnosis by histopathological diagnosis. Total interval: time (days) from detection of the first sign/symptom till histopathological diagnosis
Moodley <i>et al</i> ¹⁹	Breast	Qualitative (in depth interviews)	South Africa	Appraisal interval: time (days) between discovery of breast symptoms and perceiving reasons to seek help Help-seeking interval: time (days) between perceiving reasons to seek help and presentation to the first HCP Diagnostic interval: time (days) between assessment by the first HCP and diagnosis at the tertiary hospital.
Moodley <i>et al</i> ⁷	Breast	Cross-sectional	South Africa	Patient interval: time (days) between date of first breast change to date of first HCP consultation Diagnostic interval: time (days) between the first HCP visit and the date of diagnosis Pre-treatment interval: time (days) between date of diagnosis and the date of scheduled treatment Total time: time (days) between a woman noticing the first breast change and the date of scheduled treatment
Mujar <i>et al</i> ⁵⁴	Breast	Cross-sectional	Malaysia	Patient interval: time (months) from symptom discovery to first presentation at a primary care facility Diagnosis interval: time (months) taken from first presentation to diagnosis
Norsa'adah <i>et al</i> ⁴⁸	Breast	Cross-sectional	Malaysia	Consultation time: time (months) from symptom recognition to first general practitioner visit The time to diagnosis: time (months) from the date of the recognition of symptoms to the date of final diagnosis Diagnostic delay: more than 6 months from the recognition of symptoms to the histological diagnosis
Olarewaju <i>et al</i> ⁴⁹	Breast	Cross-sectional	Nigeria	Patient interval: time (months) between symptom detection and HCP visit; delay was considered to be a time lag of greater than 3 months Time to diagnosis: time (months) from first HCP visit to a definitive diagnosis; delay was defined as an interval exceeding 2 months

Continued

Table 1 Continued

Study ID	Cancer site	Study design	Country	Diagnostic timeliness and intervals assessed
Pace <i>et al</i> ⁵⁰	Breast	Cross-sectional	Rwanda	Patient delay: time (months) between symptom detection and first HCP visit. System delay: time (months) between the first HCP visit and definitive diagnosis
Poum <i>et al</i> ¹⁸	Breast	Cross-sectional	Thailand	Patient delay: time (days) from first reported symptoms to first HCP consultation Doctor delay: time (days) from first HCP consultation to diagnosis of breast cancer
Romanoff <i>et al</i> ⁵¹	Breast	Cross-sectional	Peru	Patient-attributable delay: time (days) from symptom onset to first medical visit Diagnosis: based on histology Health system delay: time (days) from initial medical consultation at any facility to initiation of treatment
Salih <i>et al</i> ⁵⁸	Breast	Cross sectional	Sudan	Patient delay: time (months) between symptom recognition and first HCP visit/consultation.
Shamsi <i>et al</i> ⁵⁹	Breast	Cross-sectional	Pakistan	Patient delay: time (months) between the appearances of first symptoms of breast cancer and the date of initial consultation for diagnostic mammography, ultrasonography, or medical advice.
Sharma <i>et al</i> ⁶⁰	Breast	Case-control	Haiti	Presentation interval: time (weeks) from discovery of first breast cancer sign or symptom to initial presentation to a HCP; delay defined as an interval of 12 weeks or greater
Shreyamsa <i>et al</i> ⁵³	Breast	Cross-sectional	India	Patient interval: time (months) between noticing symptoms and first consult with a medical doctor; patient delay is an interval of >3 months Provider interval: time (month) between first consultation and starting definitive treatment; provider delay is an interval >1 month
Unger-Saldaña <i>et al</i> ²⁰	Breast	Cross-sectional	Mexico	Patient interval: time (months) between the identification of the condition and the first medical consultation Diagnosis interval: time (months) from the first medical consultation to definitive diagnosis

HCP, healthcare provider.

Similarly, the thresholds for defining intervals as delayed also varied across studies. Notably, a patient interval was considered as delayed if longer than 2 months in one study,⁴⁴ whereas two other studies considered it as delayed if longer than 3 months.^{49,53} Likewise, a diagnostic interval was considered as delayed if longer than 7 days⁴⁴ but considered as delayed if longer than 1 month⁵³ and longer than 2 months⁴⁹ in other studies.

Breast cancer intervals

Appraisal and help-seeking intervals as separate intervals

Only one study assessed appraisal interval (between the detection of breast symptoms to first disclosure, eg, to partners, family and friends) and help-seeking interval (between symptom detection and first HCP visit) as separate intervals.⁵⁵ The study found a median appraisal interval of 6 days (approximately 1 week) and a median help-seeking interval of 6 weeks among women (N=420) with breast cancer in Nigeria.

Patient interval (combination of appraisal and help-seeking intervals)

In most (22/24) of the studies focusing on breast cancer, appraisal and help-seeking intervals were assessed together as a single 'patient interval' or 'time to action' (between the detection of breast symptoms and first HCP visit). The interval ranged from 10 days among breast cancer patients in Mexico (N=886)⁵² to 2 weeks in Thailand (N=180)¹⁸; 3 weeks in Colombia (N=242)⁴⁷ and South Africa (N=201)⁷; 4 weeks in Ethiopia (N=441)⁴²; 8 weeks in Malaysia (N=328)⁴⁸; 10 weeks in Malaysia (N=340)⁵⁴; 16 weeks in India (N=435)⁵³ and Libya (N=200)⁴⁰; 19 weeks in Mali (N=124)⁴³; 20 weeks in Rwanda (N=144)⁵⁰; 23 weeks in South Africa (N=20)¹⁹; 28 weeks in Peru (N=113)⁵¹; 48 weeks in Sudan (N=63)⁵⁸; 63 weeks in Pakistan (N=449)⁵⁹ and 81 weeks in Ethiopia (N=55).⁵⁶ One multicountry study (N=1429) assessed patient intervals for Namibia (1 week in non-black women and 5 weeks in

Black women), Nigeria (15 weeks), Uganda (14 weeks) and Zambia (4 weeks).⁴¹ Another multi-country study (N=6588) reported patient intervals for Bulgaria (19 weeks), India (24 weeks), Russia (19 weeks), Serbia (18 weeks) and Turkey (19 weeks).⁴⁵

Diagnostic interval

The majority (16/24) of the studies focusing on breast cancer measured diagnostic intervals (between the first HCP visit and diagnosis of breast cancer). The interval ranged from 3 weeks in Mali (N=124)⁴³ and Thailand (N=180)¹⁸; to 4 weeks in South Africa (N=201)⁷ and Malaysia (N=340)⁵⁴; 8 weeks in Colombia (N=242)⁴⁷; 10 weeks in Ethiopia (N=441)⁴²; 13 weeks in another South African study (N=20)¹⁹; 15 weeks in Nigeria (N=420)⁵⁵; 18 weeks in Mexico (N=886)⁵²; 20 weeks in Rwanda (N=144)⁵⁰ and 22 weeks in Malaysia (N=328).⁴⁸ One multicountry study (N=1429) assessed diagnostic intervals for Namibia (3 weeks in non-black women and 8 weeks in Black women), Nigeria (1 week), Uganda (19 weeks) and Zambia (10 weeks).⁴¹

Diagnostic endpoints varied across studies, with pathology (histology) being the most commonly used method, while a minority defined diagnosis based on clinical and/or radiological assessment.

Total diagnostic interval (combination of appraisal, help-seeking and diagnostic intervals)

A minority (7/24) breast cancer studies assessed total diagnostic interval (between the awareness of symptoms and diagnosis). This interval ranged from 15 weeks in Colombia (N=242)⁴⁷; to 21 weeks in Iran (N=505)³⁹; 30 weeks in Libya (N=200)⁴⁰; 34 weeks in Nigeria (N=420)⁵⁵; 36 weeks in South Africa (N=20)¹⁹; 60 weeks in Rwanda (N=144).⁵⁰ One multicountry study (N=1429) reported total diagnostic intervals for Namibia (10 weeks in non-black women and 26 weeks in Black women), Nigeria (22 weeks), Uganda (45 weeks) and Zambia (33 weeks).⁴¹

Table 2 summarises the intervals.

Cervical cancer intervals

Appraisal and help-seeking intervals as separate intervals

Neither of the two cervical studies assessed appraisal interval (between the detection of cervical symptoms to first disclosure, for example, to partners, family and friends) and help-seeking interval (between symptom detection and first HCP visit) as separate intervals.

Patient interval (combination of appraisal and help-seeking intervals)

One of the two cervical cancer studies assessed appraisal and help-seeking intervals together as a single 'patient interval' (between the detection of cervical symptoms and first HCP visit). It found a patient interval of 10 weeks among women (N=110) with cervical cancer in Nepal.⁴⁴

Diagnostic interval

One cervical cancer study evaluated diagnostic intervals (between the first HCP visit and diagnosis). It found an

interval of 8 weeks among women with cervical cancer in Nepal (N=110).⁴⁴

Total diagnostic interval (combination of appraisal, help-seeking and diagnostic intervals)

Both cervical cancer studies assessed total diagnostic interval (between the awareness of symptoms and diagnosis). The interval was 22 weeks in a cohort of women in Nepal (N=110)⁴⁴ and 30 weeks in Ethiopia (N=1575).³⁸

Factors associated with diagnostic timeliness

Appraisal and health-seeking intervals

Online supplemental table 2 summarises the factors associated with diagnostic timeliness and interval lengths across studies. Women who reported the presence of a family history of breast cancer,⁵⁹ women who reported the fear of breast cancer⁴⁵ and those that initially visited private clinics/tertiary hospitals⁴³ tended to have shorter help-seeking intervals. Also, being employed,⁴⁵ receiving supports from family/friends,⁴⁵ living in big cities,⁴⁵ receiving correct advice,⁵⁵ presence of a large tumor⁵⁵ and worsening of, or development of new symptoms⁵⁶ were associated with shorter health-seeking interval. Longer help-seeking intervals were associated with not practising self-breast examination,^{40 51} older age,^{40 42 50} not receiving a cervical examination at first consultation,⁴⁴ living in rural areas or farther away from cities,^{38 52} having ≥5 children,⁴² low health literacy level,^{7 40 42 58–60} use of traditional/complementary medicine,^{42 50 54 59} lower socioeconomic status,^{42 52 58 59} and living in denial.^{7 52} Higher family income,¹⁸ fear of high treatment cost,⁶⁰ self-medication,¹⁸ non-disclosure⁵² and seeking medical advice from family or friends¹⁸ were also associated with longer help-seeking intervals.

Diagnostic interval

Shorter diagnostic delay was associated with higher educational level,³⁹ urban residence,³⁹ ability to conduct self-breast examination³⁹ and self-detection of lump.³⁹ On the other hand, longer diagnostic interval was associated with wrong attribution of symptoms,^{41 48} low health literacy,^{19 41 44 53} symptom denial,⁷ presence of comorbidities,⁷ unemployment,^{18 46} lower socioeconomic status,^{41 52 53} older age,^{18 44 46 47 49} being unmarried,^{41 49} lay beliefs,⁴¹ residing far from a health facility^{41 44 53} and longer travel time.¹⁸ Other factors associated with longer diagnostic interval were lack of cervical examination at first consultation,⁴⁴ seeking care from multiple health practitioners and complementary/alternative care before diagnosis,^{18 46 48 50 54} health-seeking in government subsidised facilities,⁴⁷ referral delays,⁵³ false-negative diagnosis^{48 53} and poor treatment behaviour.⁴⁸ Notably, patients who initially visited private clinics/tertiary hospitals tended to have shorter help-seeking intervals but longer diagnostic delays.⁴³

DISCUSSION

Addressing the barriers to early diagnosis of breast and cervical cancer requires a sound understanding

Table 2 Diagnostic intervals and factors associated with diagnostic timeliness

Study ID	Cancer site	Country	Appraisal interval (length in weeks)	Help-seeking interval (length in weeks)	Diagnostic interval (length in weeks)	Total diagnostic interval (length in weeks)
Agodirin et al ⁵⁵	Breast	Nigeria	6 (1–28) days (1 week)	42 (7–150) days (6 weeks)	106 (13–337) days (15 weeks)	240 (90–372) days (34 weeks)
Begoihn et al ³⁸	Cervix	Ethiopia	30 (0–526) weeks			30 (0–526) weeks
Dianatinasab et al ³⁹	Breast	Iran	146 (±188) days 21 weeks			146 (±188) days 21 weeks
Dye et al ⁵⁶	Breast	Ethiopia	1.5 years 81 weeks		NR	NR
Ermiah et al ⁴⁰	Breast	Libya	4 (1–24) months 16 weeks		NR	7.5 (1–25) months 30 weeks
Foerster et al ⁴¹	Breast	Multi-country: Namibia Nigeria Uganda Zambia	Namibia (Blacks): 1.3 (0.2–6.2) months (5 weeks) Namibia (non-Black): 0.3 (0.0–2.1) months (1 week) Nigeria: 3.7 (1.0–8.1) months (15 weeks) Uganda: 3.5 (1.0–9.9) months 14 weeks Zambia: 1.1 (0.2–9.1) months (4 weeks)	1.3 (0.2–6.2) months (5 weeks) 0.3 (0.0–2.1) months (1 week) 3.7 (1.0–8.1) months (15 weeks) 3.5 (1.0–9.9) months 14 weeks 1.1 (0.2–9.1) months (4 weeks)	Namibia (Blacks): 2.0 (0.5–7.0) months (8 weeks) Namibia (non-Black): 0.7 (0.2–2.0) months (3 weeks) Nigeria: 0.2 (0.0–3.0) months (1 week) Uganda: 4.7 (1.3–11.8) months (19 weeks) Zambia: 2.6 (1.1–9.9) months (10 weeks)	Namibia (Blacks): 6.5 (2.3–13.1) months (26 weeks) Namibia (non-Black): 2.4 (0.6–5.5) months (10 weeks) Nigeria: 5.6 (2.3–13.1) months (22 weeks) Uganda: 11.3 (5.7–21.2) months (45 weeks) Zambia: 8.2 (3.4–16.4) months (33 weeks)
Gebremariam et al ⁴²	Breast	Ethiopia	30 (6–132) days (4 weeks)		69 (22–213) days (10 weeks)	NR
Grosse Frie et al ⁴³	Breast	Mali	91 (IQR NR) days 13 weeks		21 (IQR NR) days 3 weeks	NR
Gyenwali et al ⁴⁴	Cervix	Nepal	68 (8–404) days (10 weeks)		54 (0–582) days (8 weeks)	157 (22–718) days (22 weeks)
Jassem et al ⁴⁵	Breast	Multi-country: Bulgaria India Russia Serbia Turkey	Bulgaria 4.83 (±0.22) months (19 weeks) India 6.10 ((±0.33) months (24 weeks) Russia 4.81 0.17) months (19 weeks) Serbia 4.47 (±0.19) months (18 weeks) Turkey 4.84 (±0.18) months (19 weeks)	4.83 (±0.22) months (19 weeks) 6.10 ((±0.33) months (24 weeks) 4.81 0.17) months (19 weeks) 4.47 (±0.19) months (18 weeks) 4.84 (±0.18) months (19 weeks)	NR	NR

Continued

Study ID	Cancer site	Country	Appraisal interval (length in weeks)	Help-seeking interval (length in weeks)	Diagnostic interval (length in weeks)	Total diagnostic interval (length in weeks)
Khaliq <i>et al</i> ⁴⁶	Breast	Pakistan	31–128 days (4–18 weeks)		Referral interval: 7–194 days (1–27 weeks) Diagnostic interval: 15–30 days (2–4 weeks)	NR
Khokher <i>et al</i> ⁵⁷	Breast	Pakistan	<1 year for 70% of patients (<52 weeks)		NR	NR
Martínez-Pérez <i>et al</i> ⁴⁷	Breast	Colombia	20 (IQR NR) days (3 weeks)		53 (IQR NR) days (8 weeks)	104.5 (IQR NR) days (15 weeks)
Moodley <i>et al</i> ¹⁹	Breast	South Africa	164 days (average) (23 weeks)		92 days (average) (13 weeks)	256 days (average) (36 weeks)
Moodley <i>et al</i> ⁷	Breast	South Africa	23 (6–64) days (3 weeks)		28 (13–58) days (4 weeks)	NR
Mujar <i>et al</i> ⁵⁴	Breast	Malaysia	2.4 (0–120) months (10 weeks)		1 (0–9.3) months (4 weeks)	NR
Norsa'adah <i>et al</i> ⁴⁸	Breast	Malaysia	2 (0–132) months (8 weeks)		NR	5.5 (0–192) months (22 weeks)
Olarewaju <i>et al</i> ⁴⁹	Breast	Nigeria	≤3 months for 65% of patients (≤12 weeks)		≤2 months for 70% of patients (≤8 weeks)	NR
Pace <i>et al</i> ⁵⁰	Breast	Rwanda	5 (1–13) months (20 weeks)		5 (2–14) months (20 weeks)	15 (8–32) months (60 weeks)
Poum <i>et al</i> ¹⁸	Breast	Thailand	12 (IQR NR) days (2 weeks)		21 (IQR NR) days (3 weeks)	NR
Romanoff <i>et al</i> ⁵¹	Breast	Peru	198 (±449) days (28 weeks)		NR	NR
Salih <i>et al</i> ⁵⁸	Breast	Sudan	11.9 (±11.2) months (48 weeks)		NR	NR
Shamsi <i>et al</i> ⁵⁹	Breast	Pakistan	15.7 months (±25.9) 63 weeks		NR	NR
Sharma <i>et al</i> ⁶⁰	Breast	Haiti	1 (1–4) week in 58% of the patients 26 (17–77) weeks in 42% of the patients		NR	NR
Shreyamsa <i>et al</i> ⁶³	Breast	India	4 (0–24) months (16 weeks)		NR	NR
Unger-Saldaña <i>et al</i> ²⁰	Breast	Mexico	10 (IQR NR) days (1 week)		128 (IQR NR) days (18 weeks)	NR

NR, not reported.

of diagnostic timeliness, intervals and delays and the factors associated with them. This review offers up-to-date evidence with which to bolster that understanding. Overall, it demonstrates that patient-related and health-system-related delays are common in LMICs. However, it is difficult to infer and compare findings across studies owing to variations in how diagnostic time, events, intervals and delays were conceptualised and assessed. While the amount of evidence identified points to the substantial and growing attention paid to early breast and cervical cancer in LMICs over the past decade, this review has also identified gaps both in terms of quantity and methodological diversity of the available literature.

The current evidence shows a dearth of studies evaluating the timeliness of cervical cancer diagnosis, with only two of such studies identified in this review (constituting <10% of studies found). This is despite the substantial burden of cervical cancer and late-stage diagnosis in LMICs.^{1–5} Consistent with finding from previous reviews of cancer diagnostic delays,^{10 61} a major methodological issue identified by this review is the marked variability in the conceptualisation and operationalisation of the time to diagnosis and corresponding intervals. In spite of the availability of validated tools and methods for evaluating cancer diagnostic timeliness, a minority of the studies reported the use of such tools in the context of breast and cervical cancer—including the Anderson model,^{48 58} the Model of Pathways to Treatment^{7 19 43 55} and the Aarhus Statement.^{42 46}

The studies varied considerably in the use of common terminologies relating to diagnostic events and intervals. There were also variations in the thresholds used for defining delays. For instance, a patient interval was considered as delayed if longer than 2 months in one study,⁴⁴ whereas two other studies considered it as delayed if longer than 3 months.^{49 53} Similarly, different time points were used to define intervals. For instance, the end point for diagnosis was operationalised as the date of diagnosis based on clinical or imaging evaluation in some studies, while it was the date of pathological diagnosis in others. It is, therefore, important to standardise methods of assessing and reporting of diagnostic end points, one approach of which are the European Network of Cancer Registries guidelines.⁶² The wide discrepancy between the estimated patient-related intervals of 4 weeks and 81 weeks among women with breast cancer in Ethiopia, as reported by two different studies,^{42 56} starkly reflects such within-country variations. These further complicate the interpretation and comparison of findings across studies.

Patient-related intervals and delays were more frequently evaluated and reported than provider-related and health system-related ones. This is consistent with the findings of a previous review on cancer diagnostic delays in LMICs.¹⁰ The trend may be a reflection of the patient-sided way in which diagnostic delays are currently perceived in LMICs and underscores the need for more balanced and system-wide approaches to assessing and understanding the barriers to early diagnosis of breast

and cervical cancer diagnostic. It also has important implications for policy and practice. For instance, focusing on patient-centred strategies such as improving awareness, without addressing provider-related and health system-related factors, may yield limited results.

It is noteworthy that most of the studies that assessed and reported patient-related intervals did not evaluate the appraisal interval as a distinct form of patient-related interval, but rather assessed the appraisal and help-seeking intervals as a single interval. Only two studies made such distinction.^{7 55} This highlights the need for more attention to be paid to this interval among women with breast and cervical cancer symptoms as a distinct and important aspect of their journey from symptom awareness to treatment. To develop evidence-based policies and holistic interventions for addressing diagnostic delays and barriers to early cancer diagnosis in LMICs, it is imperative to understand the time and events that characterise patients' journey from the perception of bodily changes to discerning the need and urgency to seek help, as these will ultimately influence time to diagnosis and treatment.

Our review also identified a multiplicity of patient and health system-related factors associated with diagnostic timeliness and delay across specific diagnostic intervals. While the factors influencing one interval (such as the help-seeking interval) might be distinct (at least empirically) from those affecting other intervals (such as the diagnostic or provider interval), this may not be so in practice as the length of each interval is likely to be the result of a complex interplay between patient and health system drivers. For instance, women may delay help-seeking not only due to patient-related factors (such as having a low level of cancer awareness) but also due to health-system factors such as the non-availability of a health facility or HCPs.

Likewise, women with symptoms of cancer presenting at health facilities may delay definitive diagnosis following referral, due to fear of the consequences of being diagnosed with cancer (such as mastectomy, stigma and death). Hence, it is essential that these interrelationships are taken into consideration when conceptualising, evaluating and interpreting diagnostic intervals and the factors associated with them. We again emphasise the importance of standardising the assessment and reporting of cancer diagnostic intervals, to improve the translation of research findings and to better inform interventions for addressing the growing public health challenge of delayed breast and cervical cancer in resource-limited settings.

Limitations

While our review adds significantly to the existing body of literature on cancer diagnostic timeliness in LMIC contexts, it is not without limitations. First, as has been acknowledged earlier, the heterogeneous nature of the studies and the use of non-standardised methods limit the interpretation and comparability of findings. Besides, the small sample size and non-representativeness of participants of some of the studies limited both internal and external validity of the studies,

making it difficult to interpret findings in the context of their reference geographic populations.

The cross-sectional retrospective nature of many of the studies and the reliance on patients' recall to estimate events such as the time they first discovered their symptoms come with the risk of recall bias. These also come with the potential of social desirability bias that can lead to underestimation of patient and diagnostic delays. Another important limitation of this review is that, as in most scoping reviews, a formal quality appraisal of included literature was not conducted. As such, the strength of the evidence cannot be ascertained. Finally, while our literature search was comprehensive, it is possible that the review did not include all relevant literatures available, as some may not have been accessible at the time search.

CONCLUSIONS

Despite the significant burden of breast and cervical cancer in LMICs, there is limited evidence on the timeliness of diagnosis of both cancers. Available evidence demonstrates between-country and within-country variations in how diagnostic timeliness and intervals of breast and cervical cancer are conceptualised and measured in LMICs. Such variations underscore the need for the increased use of validated and standardised tools for assessing diagnostic timeliness in more reproducible and comparable ways to more accurately inform interventions for addressing the growing public health problem of diagnostic delays in LMICs.

Author affiliations

¹Women's Health Research Unit, School of Public Health and Family Medicine, University of Cape Town Faculty of Health Sciences, Cape Town, Western Cape, South Africa

²Cancer Research Initiative, University of Cape Town Faculty of Health Sciences, Cape Town, Western Cape, South Africa

³Department of Public Health, Faculty of Health Sciences, Lira University, Lira, Uganda

⁴Wolfson Institute of Population Health, Queen Mary University of London Barts and The London School of Medicine and Dentistry, London, UK

⁵Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK

Twitter Chukwudi A Nnaji @ChuxNesta_Nnaji

Acknowledgements The authors wish to thank Namhla Madini of the Faculty of Health Sciences Library, University of Cape Town, for the support and guidance in developing the literature search strategy.

Contributors JM conceived the study, provided conceptual guidance for the design of the protocol and is the guarantor of the review. CAN wrote the first draft of the manuscript. PK, FMW and JM supported the refinement of the study protocol. CAN and PK performed literature search and study selection. CAN and EE conducted full text review, data extraction and analysis. JM and FMW provided critical insights and guided the coherence of the manuscript. All authors have contributed to, and approved, the final version of the manuscript.

Funding This research was jointly supported by the Cancer Association of South Africa (CANSA), the University of Cape Town and, the SA Medical Research Council with funds received from the SA National Department of Health, GlaxoSmithKline Africa Non-Communicable Disease Open Lab (via a supporting grant Project Number: 023) and the UK Medical Research Council (via the Newton Fund). Authors retained control of the final content of the publication. FW is the Director of the multi-institutional CanTest Collaborative, which is funded by Cancer Research UK (C8640/A23385).

Map disclaimer The depiction of boundaries on the map(s) in this article does not imply the expression of any opinion whatsoever on the part of BMJ (or any member of its group) concerning the legal status of any country, territory, jurisdiction or area or of its authorities. The map(s) are provided without any warranty of any kind, either express or implied.

Competing interests None declared.

Patient consent for publication Not applicable.

Ethics approval This study does not involve human participants.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Chukwudi A Nnaji <http://orcid.org/0000-0002-4132-1922>

Elochukwu F Ezenwankwo <http://orcid.org/0000-0001-8483-9302>

Paul Kuodi <http://orcid.org/0000-0003-2483-3499>

Fiona M Walter <http://orcid.org/0000-0002-7191-6476>

Jennifer Moodley <http://orcid.org/0000-0002-9398-5202>

REFERENCES

- 1 Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Abate D, *et al*. Global, regional, and National cancer incidence, mortality, years of life lost, years lived with disability, and Disability-Adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study. *JAMA Oncol* 2019;5:1749–68.
- 2 de Sanjose S, Tsu VD. Prevention of cervical and breast cancer mortality in low- and middle-income countries: a window of opportunity. *Int J Womens Health* 2019;11:381–6.
- 3 Demment MM, Peters K, Dykens JA, *et al*. Developing the evidence base to inform best practice: a scoping study of breast and cervical cancer reviews in low- and middle-income countries. *PLoS One* 2015;10:e0134618.
- 4 Bray F, Ferlay J, Soerjomataram I, *et al*. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018;68:394–424.
- 5 GLOBOCAN. Cancer today, 2018. Available: <http://gco.iarc.fr/today/home> [Accessed 26 Mar 2021].
- 6 Dalton M, Holzman E, Erwin E, *et al*. Patient navigation services for cancer care in low- and middle-income countries: a scoping review. *PLoS One* 2019;14:e0223537-e.
- 7 Moodley J, Cairncross L, Naiker T, *et al*. From symptom discovery to treatment - women's pathways to breast cancer care: a cross-sectional study. *BMC Cancer* 2018;18:312.
- 8 Wells KJ, Battaglia TA, Dudley DJ, *et al*. Patient navigation: state of the art or is it science? *Cancer* 2008;113:1999–2010.
- 9 Valaitis RK, Carter N, Lam A, *et al*. Implementation and maintenance of patient navigation programs linking primary care with community-based health and social services: a scoping literature review. *BMC Health Serv Res* 2017;17:116.
- 10 Brand NR, Qu LG, Chao A, *et al*. Delays and barriers to cancer care in low- and middle-income countries: a systematic review. *Oncologist* 2019;24:e1371–80.
- 11 Qu LG, Brand NR, Chao A, *et al*. Interventions addressing barriers to delayed cancer diagnosis in low- and middle-income countries: a systematic review. *Oncologist* 2020;25:e1382–95.

- 12 Jedy-Agba E, McCormack V, Adebamowo C, *et al.* Stage at diagnosis of breast cancer in sub-Saharan Africa: a systematic review and meta-analysis. *Lancet Glob Health* 2016;4:e923–35.
- 13 Tegegne TK, Chojenta C, Loxton D, *et al.* The impact of geographic access on institutional delivery care use in low and middle-income countries: systematic review and meta-analysis. *PLoS One* 2018;13:e0203130.
- 14 Cazap E, Magrath I, Kingham TP, *et al.* Structural barriers to diagnosis and treatment of cancer in low- and middle-income countries: the urgent need for scaling up. *J Clin Oncol* 2016;34:14–19.
- 15 Scott SE, Walter FM, Webster A, *et al.* The model of pathways to treatment: conceptualization and integration with existing theory. *Br J Health Psychol* 2013;18:45–65.
- 16 Grosse Frie K, Samoura H, Diop S, *et al.* Why do women with breast cancer get diagnosed and treated late in sub-Saharan Africa? perspectives from women and patients in Bamako, Mali. *Breast Care* 2018;13:39–43.
- 17 Grosse Frie K, Kamaté B, Traoré CB, *et al.* Factors associated with time to first healthcare visit, diagnosis and treatment, and their impact on survival among breast cancer patients in Mali. *PLoS One* 2018;13:e0207928.
- 18 Poum A, Promthet S, Duffy SW, *et al.* Factors associated with delayed diagnosis of breast cancer in northeast Thailand. *J Epidemiol* 2014;24:102–8.
- 19 Moodley J, Cairncross L, Naiker T, *et al.* Understanding pathways to breast cancer diagnosis among women in the Western Cape Province, South Africa: a qualitative study. *BMJ Open* 2016;6:e009905.
- 20 Unger-Saldaña K, Peláez-Ballestas I, Infante-Castañeda C. Development and validation of a questionnaire to assess delay in treatment for breast cancer. *BMC Cancer* 2012;12:626.
- 21 Neal RD, Nafees S, Pasterfield D, *et al.* Patient-Reported measurement of time to diagnosis in cancer: development of the cancer symptom interval measure (C-SIM) and randomised controlled trial of method of delivery. *BMC Health Serv Res* 2014;14:3.
- 22 Walter F, Webster A, Scott S, *et al.* The Andersen model of total patient delay: a systematic review of its application in cancer diagnosis. *J Health Serv Res Policy* 2012;17:110–8.
- 23 Weller D, Vedsted P, Rubin G, *et al.* The Aarhus statement: improving design and reporting of studies on early cancer diagnosis. *Br J Cancer* 2012;106:1262–7.
- 24 Battaglia TA, Roloff K, Posner MA, *et al.* Improving follow-up to abnormal breast cancer screening in an urban population. A patient navigation intervention. *Cancer* 2007;109:359–67.
- 25 Drake BF, Tannan S, Anwuri VV, *et al.* A community-based partnership to successfully implement and maintain a breast health navigation program. *J Community Health* 2015;40:1216–23.
- 26 Neal RD, Tharmanathan P, France B, *et al.* Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? systematic review. *Br J Cancer* 2015;112 Suppl 1:S92–107.
- 27 World Health Organization (WHO). *Guide to cancer early diagnosis*. Geneva, Switzerland: World Health Organization, 2017. <http://apps.who.int/iris/bitstream/10665/254500/1/9789241511940-eng.pdf?ua=1>
- 28 World Health Organization (WHO). *WHO report on cancer: setting priorities, investing wisely and providing care for all*. Geneva: World Health Organization, 2020.
- 29 Arksey H, O'Malley L. Scoping studies: towards a methodological framework. *Int J Soc Res Methodol* 2005;8:19–32.
- 30 Levac D, Colquhoun H, O'Brien KK. Scoping studies: advancing the methodology. *Implement Sci* 2010;5:69.
- 31 Tricco AC, Lillie E, Zarin W, *et al.* PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. *Ann Intern Med* 2018;169:467–73.
- 32 Nnaji CA, Kuodi P, Walter FM, *et al.* Timeliness of diagnosis of breast and cervical cancers and associated factors in low-income and middle-income countries: a scoping review protocol. *BMJ Open* 2021;11:e044093.
- 33 McGowan J, Sampson M, Salzwedel DM, *et al.* PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement. *J Clin Epidemiol* 2016;75:40–6.
- 34 DocTranslator web site. Available: <https://www.onlinedoctranslator.com/> [Accessed 14 Mar 2021].
- 35 Peters MDJ, Godfrey CM, Khalil H, *et al.* Guidance for conducting systematic scoping reviews. *Int J Evid Based Healthc* 2015;13:141–6.
- 36 Fantom N, Serajuddin U. *The World Bank's Classification of Countries by Income (English)*. Policy Research Working Paper no. WPS 7528. Washington, DC: World Bank Group, 2016.
- 37 Carlos LL-J, LAPd C, Leopoldo VC. Effectiveness of traditional Chinese acupuncture versus sham acupuncture: a systematic review. *Rev Lat Am Enfermagem* 2016;24:e2762–e.
- 38 Begoin M, Mathewos A, Aynalem A, *et al.* Cervical cancer in Ethiopia - predictors of advanced stage and prolonged time to diagnosis. *Infect Agent Cancer* 2019;14:36.
- 39 Dianatinasab M, Fararouei M, Mohammadianpanah M, *et al.* Impact of social and clinical factors on diagnostic delay of breast cancer: a cross-sectional study. *Medicine* 2016;95:e4704.
- 40 Ermiah E, Abdalla F, Buhmeida A, *et al.* Diagnosis delay in Libyan female breast cancer. *BMC Res Notes* 2012;5:452.
- 41 Foerster M, McKenzie F, Zietsman A, *et al.* Dissecting the journey to breast cancer diagnosis in sub-Saharan Africa: findings from the multicountry ABC-DO cohort study. *Int J Cancer* 2021;148:340–51.
- 42 Gebremariam A, Addissie A, Worku A, *et al.* Time intervals experienced between first symptom recognition and pathologic diagnosis of breast cancer in Addis Ababa, Ethiopia: a cross-sectional study. *BMJ Open* 2019;9:e032228.
- 43 Grosse Frie K, Kamaté B, Traoré CB, *et al.* Health system organisation and patient pathways: breast care patients' trajectories and medical doctors' practice in Mali. *BMC Public Health* 2019;19:204.
- 44 Gyenwali D, Khanal G, Paudel R, *et al.* Estimates of delays in diagnosis of cervical cancer in Nepal. *BMC Womens Health* 2014;14:29.
- 45 Jassem J, Ozmen V, Bacanu F, *et al.* Delays in diagnosis and treatment of breast cancer: a multinational analysis. *Eur J Public Health* 2014;24:761–7.
- 46 Hameed Khaliq I, Mahmood HZ, Sarfraz MD, *et al.* Pathways to care for patients in Pakistan experiencing signs or symptoms of breast cancer. *Breast* 2019;46:40–7.
- 47 Martínez-Pérez DC, Gómez-Wolff LR, Ossa-Gómez CA, *et al.* [Association between delayed diagnosis and breast cancer in advanced clinical stage at the time of consultation in four oncology centers in Medellín- Colombia, 2017. Cross-sectional study]. *Rev Colomb Obstet Ginecol* 2020;71:87–102.
- 48 Norsaladah B, Rampal KG, Rahmah MA, *et al.* Diagnosis delay of breast cancer and its associated factors in Malaysian women. *BMC Cancer* 2011;11:141.
- 49 Olarewaju SO, Oyekunle EO, Bamiro AO. Effect of sociodemographic variables on patient and diagnostic delay of breast cancer at the Foremost health care institution in Nigeria. *J Glob Oncol* 2019;5:1–8.
- 50 Pace LE, Mpunga T, Hategekimana V, *et al.* Delays in breast cancer presentation and diagnosis at two rural cancer referral centers in Rwanda. *Oncologist* 2015;20:780–8.
- 51 Romanoff A, Constant TH, Johnson KM, *et al.* Association of previous clinical breast examination with reduced delays and Earlier-Stage breast cancer diagnosis among women in Peru. *JAMA Oncol* 2017;3:1563–7.
- 52 Unger-Saldaña K, Ventosa-Santaulària D, Miranda A, *et al.* Barriers and explanatory mechanisms of delays in the patient and diagnosis intervals of care for breast cancer in Mexico. *Oncologist* 2018;23:440–53.
- 53 Shreyamsa M, Singh D, Ramakant P, *et al.* Barriers to timely diagnosis and management of breast cancer: observations from a tertiary referral center in resource poor setting. *Indian J Surg Oncol* 2020;11:287–93.
- 54 Mohd Mular NM, Dahlui M, Emran NA, *et al.* Complementary and alternative medicine (cam) use and delays in presentation and diagnosis of breast cancer patients in public hospitals in Malaysia. *PLoS One* 2017;12:e0176394.
- 55 Agodirin O, Olatoke S, Rahman G, *et al.* Presentation intervals and the impact of delay on breast cancer progression in a black African population. *BMC Public Health* 2020;20:962.
- 56 Dye TD, Bogale S, Hobden C, *et al.* Experience of initial symptoms of breast cancer and triggers for action in Ethiopia. *Int J Breast Cancer* 2012;2012:1–5.
- 57 Khokher S, Qureshi MU, Mahmood S, *et al.* Determinants of advanced stage at initial diagnosis of breast cancer in Pakistan: adverse tumor biology vs delay in diagnosis. *Asian Pac J Cancer Prev* 2016;17:759–65.
- 58 Salih AM, Alfaki MM, Alam-Elhuda DM, *et al.* Factors delaying presentation of Sudanese breast cancer patients: an analysis using Andersen's model. *Asian Pac J Cancer Prev* 2016;17:2105–10.
- 59 Shamsi U, Khan S, Azam I, *et al.* Patient delay in breast cancer diagnosis in two hospitals in Karachi, Pakistan: preventive and Life-Saving measures needed. *JCO Glob Oncol* 2020;6:873–83.
- 60 Sharma K, Costas A, Damuse R, *et al.* The Haiti breast cancer initiative: initial findings and analysis of Barriers-to-Care delaying patient presentation. *J Oncol* 2013;2013:1–6.

- 61 Gbenonsi G, Boucham M, Belrhiti Z, *et al.* Health system factors that influence diagnostic and treatment intervals in women with breast cancer in sub-Saharan Africa: a systematic review. *BMC Public Health* 2021;21:1325.
- 62 European Network of Cancer Registries (ENCR). Recommendations for coding incidence date, 1997. Available: <https://www.encreu/sites/default/files/pdf/incideng.pdf> [Accessed 27 Aug 2021].